Supplier
ST Jude Childrens Research Hospital INC
ST Jude Childrens Research Hospital INC was paid $5.07M by Medicaid between Jan 2018 and Nov 2024, across 141 billing codes. Its largest line is 70553, Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences — 13% of everything it billed.
33Billing provider infoST JUDE CHILDRENS RESEARCH HOSPITAL INC
MEMPHIS, TN 38105
MEMPHIS, TN 38105
33aNPI1033112230assigned 05/23/2005
33bProvider typeClinic Pharmacy
28Total paid$5.07M
24GClaims334,801
24DCodes billed141
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 60,804 | $1.06M | |
| 2019 | 58,941 | $1.08M | |
| 2020 | 39,745 | $660K | |
| 2021 | 47,495 | $793K | |
| 2022 | 45,296 | $550K | |
| 2023 | 50,127 | $568K | |
| 2024incomplete | 32,393 | $364K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 13% | 2,792 | 2,288 | $664K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 8.5% | 53,559 | 32,492 | $432K |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | 8.4% | 1,316 | 913 | $428K |
| 80053 | Comprehensive metabolic panel | 8.3% | 37,302 | 22,986 | $421K |
| 36430 | 5.6% | 1,609 | 966 | $285K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.7% | 824 | 670 | $189K |
| 96409 | 3.5% | 1,635 | 704 | $179K | |
| 86900 | 3.5% | 4,916 | 3,152 | $176K | |
| 83021 | 3.4% | 8,305 | 6,997 | $172K | |
| 83735 | 2.5% | 24,394 | 11,129 | $129K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.4% | 759 | 273 | $123K |
| 83615 | 2.3% | 20,923 | 13,909 | $118K |
129 more codes
| 85045 | 2.2% | 25,562 | $112K | |
| 86920 | 2.0% | 801 | $102K | |
| 86850 | 1.9% | 4,807 | $96K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 2,232 | $94K |
| 84100 | 1.8% | 24,136 | $90K | |
| A9585 | Injection, gadobutrol, 0.1 ml | 1.7% | 3,473 | $89K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 2,171 | $87K |
| 86901 | 1.5% | 4,920 | $78K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.5% | 3,155 | $77K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 4,362 | $59K |
| 82248 | <1% | 9,244 | $49K | |
| 82728 | <1% | 3,480 | $46K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,988 | $42K |
| 84550 | <1% | 11,623 | $42K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 290 | $39K |
| J2704 | Injection, propofol, 10 mg | <1% | 10,141 | $37K |
| 86922 | <1% | 444 | $34K | |
| 82610 | <1% | 2,857 | $32K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,394 | $30K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 957 | $29K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 704 | $28K |
| 92018 | <1% | 58 | $25K | |
| 83020 | <1% | 1,561 | $24K | |
| 87536 | <1% | 421 | $20K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 182 | $19K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 686 | $19K |
| 82043 | <1% | 1,281 | $16K | |
| 90674 | <1% | 1,113 | $16K | |
| 84703 | <1% | 2,583 | $15K | |
| 86902 | <1% | 482 | $15K | |
| 88184 | <1% | 94 | $15K | |
| 82570 | <1% | 1,653 | $14K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,929 | $13K |
| 36592 | <1% | 964 | $11K | |
| 90686 | <1% | 937 | $11K | |
| 82784 | <1% | 997 | $9K | |
| 86361 | <1% | 224 | $8K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 178 | $8K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 375 | $8K |
| 84439 | <1% | 1,703 | $8K | |
| 92567 | <1% | 591 | $8K | |
| 90651 | <1% | 30 | $8K | |
| 81003 | <1% | 4,417 | $7K | |
| 97164 | <1% | 276 | $7K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 111 | $7K |
| 86140 | <1% | 1,982 | $7K | |
| 80050 | General health panel | <1% | 825 | $7K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 39 | $6K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 43 | $6K |
| 97168 | <1% | 200 | $5K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 1,011 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 296 | $5K |
| 81001 | <1% | 1,861 | $5K | |
| 92523 | <1% | 60 | $5K | |
| 85027 | <1% | 1,014 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,650 | $4K |
| 84156 | <1% | 1,397 | $4K | |
| 92250 | <1% | 188 | $4K | |
| 87799 | <1% | 79 | $4K | |
| 88108 | <1% | 252 | $4K | |
| 82533 | <1% | 261 | $4K | |
| 0399T | <1% | 82 | $4K | |
| 84466 | <1% | 404 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,068 | $3K |
| 83002 | <1% | 358 | $3K | |
| J9250 | Methotrexate sodium, 5 mg | <1% | 916 | $3K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,153 | $3K |
| 90661 | <1% | 171 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,968 | $3K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 63 | $3K |
| 93888 | <1% | 33 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 62 | $3K |
| 83540 | <1% | 557 | $3K | |
| 62270 | <1% | 14 | $2K | |
| 88185 | <1% | 27 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 171 | $2K |
| 90620 | <1% | 19 | $2K | |
| 89051 | <1% | 557 | $2K | |
| 87497 | <1% | 79 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 66 | $2K |
| 36591 | <1% | 249 | $2K | |
| 87103 | <1% | 98 | $1K | |
| 83001 | <1% | 151 | $1K | |
| 76376 | <1% | 229 | $1K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 180 | $937.60 |
| 87486 | <1% | 39 | $886.12 | |
| 87581 | <1% | 39 | $886.12 | |
| 80061 | Lipid panel | <1% | 99 | $867.73 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 119 | $811.21 |
| 87040 | <1% | 96 | $697.55 | |
| 93356 | <1% | 271 | $686.57 | |
| 86360 | <1% | 24 | $676.44 | |
| 92133 | <1% | 29 | $657.50 | |
| 83525 | <1% | 103 | $627.60 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 79 | $563.87 |
| 86355 | <1% | 24 | $538.10 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 107 | $531.36 |
| 86357 | <1% | 24 | $528.71 | |
| 86359 | <1% | 24 | $528.70 | |
| 86706 | <1% | 62 | $480.63 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 43 | $469.62 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 594 | $447.20 |
| 96411 | <1% | 18 | $405.34 | |
| 87535 | <1% | 12 | $361.14 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 261 | $354.26 |
| 90734 | <1% | 27 | $311.80 | |
| 92552 | <1% | 29 | $272.32 | |
| J9100 | Injection, cytarabine, 100 mg | <1% | 103 | $226.86 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 74 | $199.89 |
| 87340 | <1% | 32 | $184.45 | |
| 82670 | <1% | 14 | $161.04 | |
| 84305 | <1% | 24 | $160.70 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 226 | $151.27 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 14 | $145.65 |
| 82330 | <1% | 13 | $139.09 | |
| 90685 | <1% | 24 | $136.26 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 48 | $131.58 |
| A4618 | Breathing circuits | <1% | 92 | $97.96 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 30 | $95.83 |
| 86704 | <1% | 13 | $95.22 | |
| 85730 | <1% | 18 | $70.24 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14 | $60.51 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 25 | $53.35 |
| 92556 | <1% | 28 | $53.10 | |
| S0080 | Injection, pentamidine isethionate, 300 mg | <1% | 32 | $52.29 |
| 85610 | <1% | 16 | $34.56 | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 21 | $24.09 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 35 | $11.45 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 28 | $3.64 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKEEL, PATRICIA (SVP/CFO)
| Provider | Location | Paid |
|---|---|---|
| ST Jude Children's Research Hospital, INC. | Memphis, TN | $1.19M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.